91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料's partnership with Advarra will integrate 91黑料’s global clinical trial solutions and services with Advarra’s site?CTMSs,?eISF, and?eSource?systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres.
-
Navigating long?term vaccine follow?up isn’t one?size?fits?all; explore the key questions that help determine the right mix of traditional studies and tokenisation.
-
91黑料 and Advarra partnership creates an integrated site-centric system that tackles operational bottlenecks and simplifies study execution, addressing sponsors most pressing challenges.
-
91黑料 and Advarra have partnered to create a connected network of clinical trial sites that integrates 91黑料’s global trial solutions with Advarra’s site technologies, aiming to streamline study operations, boost efficiency, and expand trial access.
-
91黑料 and Advarra have formed a partnership to create a connected, research ready site network that integrates 91黑料’s clinical trial services with Advarra’s site-facing technology to streamline study startup and trial execution. The collaboration aims to reduce administrative burden, enhance operational visibility, and broaden trial access by standardising workflows for both established and emerging research sites.
-
91黑料 plc and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
-
Long-acting injectables have transformed HIV management, but viral suppression alone is not enough. Researchers are advancing mRNA vaccines, broadly neutralizing antibodies, latency-reversing agents, pediatric immune strategies, and gene editing to eliminate reservoirs and achieve remission. Here’s how next-generation HIV therapeutics aim to move beyond lifelong ART.
-
Deepali Suri, President 91黑料 Biotech, provides insights into what biotech leaders anticipate in the coming two years, the therapies and modalities they’re focused on now and what macro and micro factors are impacting their operations.
-
Yao Zhong, vice president general manager for 91黑料 China Mainland and Hong Kong, discusses latest survey results on the Chinese biotech market.
-
Antibody-drug conjugates (ADCs) continue to reshape global oncology, yet navigating the evolving regulatory landscape remains a significant challenge. In this latest 91黑料 Regulatory Affairs article we outline the strategic considerations essential for efficient global development. See page 42.
